| Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer (NCT07730138) | Daewoong Pharmaceutical Co. LTD. | 2026-10-15 |
| To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus (NCT07619833) | Daewoong Pharmaceutical Co. LTD. | 2026-06-01 |
| A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers (NCT07539415) | Daewoong Pharmaceutical Co. LTD. | 2026-05-06 |
| Fexuclue for Prevention of NSAIDs-Induced Peptic Ulcer in Real-World Practice (NCT07558707) | Daewoong Pharmaceutical Co. LTD. | 2026-04-30 |
| Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study (NCT07515560) | Daewoong Pharmaceutical Co. LTD. | 2026-04-30 |
| Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer (NCT07371104) | Daewoong Pharmaceutical Co. LTD. | 2026-04-22 |
| Noseguard for Prevention of Respiratory Infections in Real-World Use (NCT07516977) | Daewoong Pharmaceutical Co. LTD. | 2026-04-20 |
| Study to Evaluate the Efficacy and Safety of Fexuprazan in Prevention of NSAIDs Induced Peptic Ulcer (NCT07533266) | Daewoong Pharmaceutical Co. LTD. | 2026-04-01 |
| Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition. (NCT07267221) | Daewoong Pharmaceutical Co. LTD. | 2025-12-01 |
| PK and Safety Comparison of DWJ445 and DWC202506 in Healthy Volunteers (NCT07256600) | Daewoong Pharmaceutical Co. LTD. | 2025-11-14 |
| Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults (NCT07213310) | Daewoong Pharmaceutical Co. LTD. | 2025-11-09 |
| Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting Conditions (NCT07260851) | Daewoong Pharmaceutical Co. LTD. | 2025-11-05 |
| Phase 4 Multicenter, Open-label Study on Efficacy and Safety of Apremilast in Moderate-to-severe Psoriasis (NCT07190391) | Daewoong Pharmaceutical Co. LTD. | 2025-09-30 |
| Observational Study to Evaluate the Efficacy of OLMETEC Tab on Nocturnal Blood Pressure Control in Patients With Stage Ⅰ Hypertension (NCT07515599) | Daewoong Pharmaceutical Co. LTD. | 2025-09-17 |
| PK and Safety Comparison of DWJ1511 and DWC202501 in Healthy Volunteers (NCT07144176) | Daewoong Pharmaceutical Co. LTD. | 2025-09-01 |
| Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines (NCT07013279) | Daewoong Pharmaceutical Co. LTD. | 2025-07-15 |
| Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis (NCT06948487) | Daewoong Pharmaceutical Co. LTD. | 2025-06-17 |
| A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension (NCT06671392) | Daewoong Pharmaceutical Co. LTD. | 2025-02-24 |
| Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension (NCT06682000) | Daewoong Pharmaceutical Co. LTD. | 2025-01-20 |
| Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia (NCT06647888) | Daewoong Pharmaceutical Co. LTD. | 2024-12-03 |
| Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults (NCT06644404) | Daewoong Pharmaceutical Co. LTD. | 2024-10-26 |
| Bioepuivalence Study for the Safety and the Pharmacokinetics of DWJ1589 and DWC202315 (NCT06592495) | Daewoong Pharmaceutical Co. LTD. | 2024-10-01 |
| to Evaluate the Safety/Tolerability and Pharmacokinetics, and Pharmacodynamics of DWP14012 Injection (NCT06437951) | Daewoong Pharmaceutical Co. LTD. | 2024-07-01 |
| Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes Mellitus (NCT06427083) | Daewoong Pharmaceutical Co. LTD. | 2024-06-11 |
| Effect of Linking Data Using Smartphone Application, 'Well Check', on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus (NCT06419816) | Daewoong Pharmaceutical Co. LTD. | 2024-06-11 |
| Efficacy and Safety of DWJ1609 for Bowel Cleansing Before Colonoscopy; (NCT06062030) | Daewoong Pharmaceutical Co. LTD. | 2024-03-08 |
| Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori (NCT06751121) | Daewoong Pharmaceutical Co. LTD. | 2024-02-06 |
| Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus (NCT06141980) | Daewoong Pharmaceutical Co. LTD. | 2023-12-01 |
| Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines (NCT06212960) | Daewoong Pharmaceutical Co. LTD. | 2023-11-28 |
| Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1568 in Healthy Adult Volunteers (NCT06119945) | Daewoong Pharmaceutical Co. LTD. | 2023-11-09 |
| Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1567 in Healthy Adult Volunteers (NCT06109259) | Daewoong Pharmaceutical Co. LTD. | 2023-11-06 |
| Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects (NCT06119958) | Daewoong Pharmaceutical Co. LTD. | 2023-10-27 |
| To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus (NCT05926414) | Daewoong Pharmaceutical Co. LTD. | 2023-09-21 |
| Efficacy and Safety of Switching to Vemliver From Entecavir in Chronic Hepatitis B Patients Previously Treated With Entecavir (NCT06000657) | Daewoong Pharmaceutical Co. LTD. | 2023-08-28 |
| Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1558 in Healthy Adult Volunteers (NCT06010589) | Daewoong Pharmaceutical Co. LTD. | 2023-08-17 |
| Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1543 With DWC202307 in Healthy Adult Volunteers (NCT05954338) | Daewoong Pharmaceutical Co. LTD. | 2023-08-01 |
| Evaluate the Efficacy and Safety of DWJ108J (NCT06025409) | Daewoong Pharmaceutical Co. LTD. | 2023-08-01 |
| Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1543 in Healthy Adult Volunteers (NCT05954247) | Daewoong Pharmaceutical Co. LTD. | 2023-08-01 |
| A Study to Evaluate the Efficacy and Safety of CREZET Tablet (NCT05889143) | Daewoong Pharmaceutical Co. LTD. | 2023-05-24 |
| Study to Evaluate the Efficacy and Safety of FEXUCLUE Tablet (NCT05886933) | Daewoong Pharmaceutical Co. LTD. | 2023-05-22 |
| To Compare the Safety and PK/PD Characteristics of Subjects With Between Hepatic Impairment and Normal Hepatic Function (NCT05747664) | Daewoong Pharmaceutical Co. LTD. | 2023-04-13 |
| A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus (NCT05466643) | Daewoong Pharmaceutical Co. LTD. | 2023-03-17 |
| A Clinical Study to Investigate the Mass Balance and Biotransformation of [14C]DWP14012 in Healthy Chinese Male Subjects (NCT05868967) | Daewoong Pharmaceutical Co. LTD. | 2023-02-27 |
| A Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Concomitant Hypertension and Hyperlipidemia (NCT05643508) | Daewoong Pharmaceutical Co. LTD. | 2023-02-23 |
| Drug-drug Interactions Between DWC202211 and DWC202212 in Healthy Subjects (NCT05699070) | Daewoong Pharmaceutical Co. LTD. | 2023-02-15 |
| Study to Evaluate the Efficacy and Safety of DWJ1464 in Patients with Chronic Liver Disease (NCT06272630) | Daewoong Pharmaceutical Co. LTD. | 2023-02-06 |
| To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose Combination (NCT05737771) | Daewoong Pharmaceutical Co. LTD. | 2023-01-25 |
| A Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab (NCT05660122) | Daewoong Pharmaceutical Co. LTD. | 2022-11-11 |
| Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects (NCT05812404) | Daewoong Pharmaceutical Co. LTD. | 2022-10-26 |
| The Safety, Tolerability, PK, and PD of DWP213388 After SAD and MAD Administration in Healthy Adult Subjects (NCT05607589) | Daewoong Pharmaceutical Co. LTD. | 2022-10-01 |
| The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin (NCT05505994) | Daewoong Pharmaceutical Co. LTD. | 2022-09-28 |
| Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects (NCT05574374) | Daewoong Pharmaceutical Co. LTD. | 2022-09-21 |
| Drug-Drug Interaction of DWP16001 in Combination With DWC202204 and DWC202205 in Healthy Male Adults (NCT05500898) | Daewoong Pharmaceutical Co. LTD. | 2022-08-26 |
| Assessment of Elemental Impurities Level After Multiple Administration of DWJ1230 or DWB2001 in Subjects With Functional Diarrhea or Irritable Bowel Syndrome With Predominant Diarrhea. (NCT05816681) | Daewoong Pharmaceutical Co. LTD. | 2022-08-22 |
| Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF (NCT05389215) | Daewoong Pharmaceutical Co. LTD. | 2022-07-29 |
| Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics of DWP16001 Drug A and C (NCT05465668) | Daewoong Pharmaceutical Co. LTD. | 2022-07-22 |
| Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab (NCT05614752) | Daewoong Pharmaceutical Co. LTD. | 2022-07-06 |
| Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia (NCT05660135) | Daewoong Pharmaceutical Co. LTD. | 2022-06-20 |
| Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab (NCT05411887) | Daewoong Pharmaceutical Co. LTD. | 2022-06-20 |
| DWP708 for Treating Epidermal Growth Factor Receptor Inhibitor Related Skin Toxicities (NCT05378360) | Daewoong Pharmaceutical Co. LTD. | 2022-05-02 |
| A Crossover Study of DWJ1525 to Evaluate the Safety and Pharmacokinetic Properties in Healthy Volunteers (NCT05192395) | Daewoong Pharmaceutical Co. LTD. | 2022-04-15 |
| Clinical Trials to Assess Safety and Efficacy of DWRX2003 Combination With Remdesivir in Moderate to Severe COVID-19 Patients. (NCT05226533) | Daewoong Pharmaceutical Co. LTD. | 2022-03-31 |
| Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects (NCT05304845) | Daewoong Pharmaceutical Co. LTD. | 2022-03-21 |
| To Evaluate Improvement Effect of Subjective Symptoms of Mucotra SR Tablet in Patients With Gastritis (NCT06668506) | Daewoong Pharmaceutical Co. LTD. | 2022-03-17 |
| To Investigate Blood Lipid Changes and Safety After Litorvazet® Tablets in Dyslipidemia Patients (NCT06866509) | Daewoong Pharmaceutical Co. LTD. | 2022-02-28 |
| Study to Investigate the Efficacy and Safety After Administration of Daewoong Zoledronic Acid for the Purpose of Treatment or Prevention of Osteoporosis (NCT05614778) | Daewoong Pharmaceutical Co. LTD. | 2022-02-28 |
| Study to Evaluate the Safety and PK Properties of DWP16001 in Healthy Subjects With Various Ethnicities (NCT05207176) | Daewoong Pharmaceutical Co. LTD. | 2022-02-14 |
| An Exploratory Clinical Trial to Evaluate and Compare Safety and Pharmacokinetic Characteristics After Administration of the DWJ1439, DWJ1464, DWC202108 or DWC202109 in Healthy Adult Volunteers (NCT05832697) | Daewoong Pharmaceutical Co. LTD. | 2022-01-27 |
| Study to Evaluate the Safety/Tolerability, PK and PD After Intravenous DWJ1521 Administration in Healthy Volunteers (NCT06508645) | Daewoong Pharmaceutical Co. LTD. | 2022-01-10 |
| The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis (NCT05813561) | Daewoong Pharmaceutical Co. LTD. | 2021-12-30 |
| The Drug Interaction of DWP16001 and DWC202010 After Oral Administration in Healthy Adults (NCT05321732) | Daewoong Pharmaceutical Co. LTD. | 2021-12-10 |
| Evaluate the Pharmacokinetics and Safety of DWP14012 Tablet A and Compare Those of DWP14012 Tablet B in Healthy Subjects (NCT05149274) | Daewoong Pharmaceutical Co. LTD. | 2021-10-01 |
| Clinical Trial to Compare Rebamipide/Nizatidine Combination Therapy With Nizatidine Monotherapy in Patients With Gastritis (NCT05072938) | Daewoong Pharmaceutical Co. LTD. | 2021-09-30 |
| Study to Evaluate the Long Term Safety and Efficacy of DWP16001 Compared to Placebo in the Treatment of T2DM. (NCT05376930) | Daewoong Pharmaceutical Co. LTD. | 2021-09-16 |
| To Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After Gasterectomy (NCT05410535) | Daewoong Pharmaceutical Co. LTD. | 2021-09-15 |
| To Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Volunteers (NCT04888728) | Daewoong Pharmaceutical Co. LTD. | 2021-06-30 |
| Freestyle Libre-based Education on MDI in T2DM (FreEdoM-2) (NCT04926623) | Daewoong Pharmaceutical Co. LTD. | 2021-06-17 |
| A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2 (NCT04721535) | Daewoong Pharmaceutical Co. LTD. | 2021-06-07 |
| Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer (NCT04784910) | Daewoong Pharmaceutical Co. LTD. | 2021-05-21 |
| Pharmacokinetics and Safety Following Administration of DWP16001 (NCT05414591) | Daewoong Pharmaceutical Co. LTD. | 2021-05-01 |
| To Evaluate Food Effect on the PK and Safety After Oral DWN12088 Administration in Healthy Adult Volunteers (NCT04767815) | Daewoong Pharmaceutical Co. LTD. | 2021-03-22 |
| Pharmacokinetics and Safety of DWJ1451 in Healthy Adults (NCT04819932) | Daewoong Pharmaceutical Co. LTD. | 2021-03-13 |
| Safety and Pharmacokinetics Evaluation Study According to the Dose of Camostat Mesylate in Healthy Volunteers (NCT04782505) | Daewoong Pharmaceutical Co. LTD. | 2021-03-12 |
| Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients (NCT04713176) | Daewoong Pharmaceutical Co. LTD. | 2021-02-02 |
| Evaluate the Efficacy and Safety of DWJ1506 and DWJ1507 (NCT04772443) | Daewoong Pharmaceutical Co. LTD. | 2021-02-01 |
| Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics After Intravenous DWJ1521 Administration in Healthy Adult Volunteers (NCT04827472) | Daewoong Pharmaceutical Co. LTD. | 2021-01-20 |
| The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus (NCT04654390) | Daewoong Pharmaceutical Co. LTD. | 2020-12-30 |
| To Evaluate Safety, Tolerability and Pharmacodynamics of DWRX2003 Against COVID-19 (in Philippines) (NCT04541485) | Daewoong Pharmaceutical Co. LTD. | 2020-12-04 |
| To Assess the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Which is the Treatment of COVID-19 in Healthy Volunteers. (NCT04749173) | Daewoong Pharmaceutical Co. LTD. | 2020-11-21 |
| The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes. (NCT04634500) | Daewoong Pharmaceutical Co. LTD. | 2020-11-18 |
| Treatment Effect According to Timing of Administration of DWP14012 40 mg (NCT04613895) | Daewoong Pharmaceutical Co. LTD. | 2020-11-17 |
| The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus. (NCT04632862) | Daewoong Pharmaceutical Co. LTD. | 2020-11-11 |
| To Evaluate the Safety, Tolerability and Pharmacokinetic Properties of DWRX2003 (NCT04592835) | Daewoong Pharmaceutical Co. LTD. | 2020-10-19 |
| Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo (NCT04521296) | Daewoong Pharmaceutical Co. LTD. | 2020-09-11 |
| Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers (NCT04328766) | Daewoong Pharmaceutical Co. LTD. | 2020-09-06 |
| DWP450 for Treating Moderate to Severe Glabellar Lines (NCT06354127) | Daewoong Pharmaceutical Co. LTD. | 2020-08-12 |
| Safety and Pharmacokinetics of DWJ1439, DWJ1464, DWC202003 or DWC202004 in Healthy Volunteers (NCT04477369) | Daewoong Pharmaceutical Co. LTD. | 2020-08-06 |
| To Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of DWRX2003 Against COVID-19 (NCT04524052) | Daewoong Pharmaceutical Co. LTD. | 2020-08-01 |
| Study to Evaluate the Efficacy and Safety of DWP14012 on Maintaining Healing in Subjects With Healed Erosive Esophagitis (NCT04341428) | Daewoong Pharmaceutical Co. LTD. | 2020-07-02 |
| Drug-drug Interaction Between DWP14012 and Three Different Kinds of NSAIDs (NCT04490434) | Daewoong Pharmaceutical Co. LTD. | 2020-06-19 |